why insulin

Diabetes: a burden in the mena

Burdens linked with diabetes are usually related to cost of therapy and associated complications which particularly arise in Less Economically Developed Countries where the full unsubsidised price of medication remains unaffordable.

According to IDF estimations:*
- The total health expenditure in 2010 was $5.6 billion which is estimated in 2030 to reach $11.4 billion
- Diabetes mortality rates in 2010 were estimated between 117-177 thousand deaths.

Addressing the problem

One of the most significant milestones in our venture into biotechnology is the manufacturing of JuslineŽ the Julphar brand for recombinant human Insulin - a major step towards diabetes care in the region which was originally manufactured from European sourced API crystals and marketed in 14 countries worldwide.

Jusline (r-DNA insulin) is clinically validated and meets the highest global standard which is furthermore supplemented by strong clinical data base through comparative clinical trials and bioequivalence studies conducted at one of most reputable diabetes research centres in the region. It is available in 10 ml vials of 100 u/ml in three different formulations JuslineŽ R (regular), JuslineŽ N (basal) and JuslineŽ 30/70 (Biphasic) which cover all aspects of insulin requirement for diabetics.

 Today JuslineŽ offers to health care providers and patients high quality recombinant human insulin at an affordable price which also supports governments with a strategic alternative to reduce the cost burden of diabetes thus increasing accessibility of insulin therapy.